Total
0
Shares
Emerald Clinics (ASX:EMD) - Managing Director & CEO, Michael Winlo
Managing Director & CEO, Michael Winlo
Source: WA Business News
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Emyria (EMD) has added a second Emerald Clinic consulting suite in Perth due to strong growth
  • The company says the expansion comes off the back of record patient appointments in January 2021 and the recent growth in Victoria
  • The new Perth suite will have the capacity for four additional consulting rooms
  • Additionally, the new clinic will also support the clinical trials being planned for Emyria’s first drug development program, EMD-003
  • On market close for the day, Emyria is down 2.56 per cent and trading at 19 cents per share

Emyria (EMD) has added a second Emerald Clinic consulting suite in Perth due to strong growth.

The company says the expansion comes off the back of record patient appointments in January 2021 and the recent growth in Victoria.

The new Perth suite will have the capacity for four additional consulting rooms and is co-located within the site of West Leederville Private Hospital complex.

Additionally, the new clinic will also support the clinical trials being planned for Emyria’s first drug development program, EMD-003, targeting unmet needs in
mental health.

EMD-003 is the company’s first cannabinoid-based medicine, which Emyria is aiming to have Australia’s Therapeutic Goods Administration approve.

“Western Australia was the first Emerald Clinics location. Demand for our services from both patients and referring doctors has grown every month since we opened,” Managing Director Michael Winlo said.

“We anticipate this expansion will allow us to improve our waiting times and see more patients which, in turn, improves our proprietary data asset,” he added.

Notably, this expansion has the potential to double the capacity of Perth.

On market close for the day, Emyria is down 2.56 per cent and trading at 19 cents per share.

EMD by the numbers
More From The Market Herald
Advanced Human Imaging, AHI- CEO and Co-Founder Vlado Bosanac

" Advanced Human Imaging (ASX:AHI) appoints Edward F. Greissing Jr. to board

Advanced Human Imaging (AHI) has appointed Edward F. Greissing Jr. to board effective from November 30, 2021.
Rhythm Biosciences (ASX:RHY) - CEO, Glenn Gilbert

" Rhythm Biosciences (ASX:RHY) achieves CE Mark for ColoSTAT

Cancer diagnostic technology company Rhythm Biosciences (RHY) has achieved CE Mark certification for ColoSTAT.
EMVision Medical Devices (ASX:EMV) - CEO, Ron Weinberger

" EMVision Medical Devices (ASX:EMV) reports more strong results

Medical device maker EMVision (EMV) is spiking on the ASX today after releasing further results from a pilot clinical trial of its brain
ECS Botanics (ASX:ECS) - Managing Director and Founder, Alex Keach

" ECS Botanics’ (ASX:ECS) subsidiary buds $4.9m supply agreement

ECS Botanics’ (ECS) subsidiary has secured a $4.9 million agreement to supply resin to Australian cannabis company, Cannvalate.